Legend Biotech Bundle
What is Legend Biotech's Story?
The U.S. FDA's February 2022 approval of Carvykti (ciltacabtagene autoleucel) was a landmark event for Legend Biotech, establishing it as a key player in cell therapy for multiple myeloma. This was quickly followed by European authorization, highlighting the company's swift rise.
Founded in 2014 in Nanjing, China, Legend Biotech began as an early-stage cell therapy venture. Its initial focus was on developing innovative cell therapies to address critical unmet needs in hematologic malignancies.
Legend Biotech is now a global, commercial-stage biotechnology firm leading the CAR-T cell therapy field. Its primary product, Carvykti, achieved approximately $439 million in net trade sales in Q2 2025, with over 7,500 patients treated. This growth reflects its dedication to scientific advancement and patient care, as detailed in the Legend Biotech PESTEL Analysis.
What is the Legend Biotech Founding Story?
Legend Biotech was established in 2014 by Frank Fan, initially as the 'Legend Project,' an early-stage cell therapy initiative within GenScript Biotech. The company's genesis was driven by a team of scientists focused on addressing the significant unmet need in treating relapsed and refractory multiple myeloma.
The Genesis of a Pioneer
Founded in 2014, Legend Biotech began as the 'Legend Project' under GenScript Biotech, driven by a mission to revolutionize cancer treatment. The company's early focus was on developing innovative cell therapies, particularly CAR-T cells targeting BCMA.
- Founded in 2014 by Frank Fan
- Initial operations as the 'Legend Project' within GenScript Biotech
- Focus on cell therapy, specifically CAR-T targeting BCMA
- Early operations were modest, reportedly in a small room
The foundational business model of Legend Biotech centered on the discovery and development of novel cell therapies, with a specific emphasis on chimeric antigen receptor T-cells (CAR-T) designed to target the B-cell maturation antigen (BCMA) protein. This strategic decision positioned Legend Biotech as one of the earliest global entities to engineer CAR-T cells for BCMA, a move that would significantly shape its future development and market presence. The initial operations were conducted on a small scale, with the 'Legend Project' operating from a limited space. Funding for these early stages was provided by its parent company, GenScript Biotech.
A pivotal moment in the company's early history was the commencement of investigator-initiated trials for its BCMA CAR-T candidate in China in 2016. The promising outcomes from these initial trials were subsequently presented at the American Society for Clinical Oncology (ASCO) in 2017. This presentation garnered considerable attention from major pharmaceutical corporations, marking a significant turning point for the company. This led to a crucial worldwide license and collaboration agreement with Janssen Biotech, Inc., a subsidiary of Johnson & Johnson, in December 2017. The agreement was for the joint development and commercialization of the BCMA CAR-T therapy, then identified as LCAR-B38M and later as ciltacabtagene autoleucel (cilta-cel). This collaboration provided Legend Biotech with substantial upfront funding amounting to $350 million and established a 50/50 arrangement for sharing costs and profits from worldwide sales, with the exception of Greater China. This partnership was a key step in the Marketing Strategy of Legend Biotech.
Legend Biotech SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
What Drove the Early Growth of Legend Biotech?
Following its founding in 2014, Legend Biotech entered a period of significant expansion, notably after a crucial partnership with Janssen in December 2017. This collaboration accelerated the development of its lead CAR-T candidate, cilta-cel, leading to promising clinical trial results in multiple myeloma patients.
Accelerated Development Post-Partnership
The partnership with Janssen provided a substantial boost to Legend Biotech's development efforts for cilta-cel. Clinical trials quickly demonstrated profound and durable responses, solidifying the company's position and attracting further investment.
Early Regulatory Milestones and Global Expansion
In 2018, the company submitted its first Biologics License Application (BLA) in China for cilta-cel. Simultaneously, Legend Biotech established its U.S. headquarters in Somerset, New Jersey, to support global development and future commercialization.
Public Offering and Continued Clinical Success
June 2020 marked a significant financial milestone with Legend Biotech's initial public offering (IPO) on NASDAQ, raising substantial capital. This funding supported ongoing research, manufacturing expansion, and commercialization activities, further fueled by positive topline data from the CARTITUDE-1 study in 2021.
Strategic Focus on Clinical Execution and Alliances
This early growth phase was characterized by a strong emphasis on clinical execution and the formation of strategic alliances. These efforts were instrumental in positioning Legend Biotech as a key player in the rapidly evolving cell therapy sector, a testament to its Revenue Streams & Business Model of Legend Biotech.
Legend Biotech PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
What are the key Milestones in Legend Biotech history?
Legend Biotech's journey has been marked by significant milestones, pioneering innovations, and formidable challenges inherent in the highly complex field of cell therapy. A groundbreaking achievement was the U.S. FDA approval of Carvykti (ciltacabtagene autoleucel) in February 2022, for the treatment of adults with relapsed or refractory multiple myeloma. This was swiftly followed by conditional marketing authorization from the European Commission in May 2022, and approval in Japan in September 2022, broadening its global reach. The FDA further expanded Carvykti's label in April 2024 to include patients who have received at least one prior line of therapy, significantly moving it into earlier lines of treatment.
| Year | Milestone |
|---|---|
| 2022 | U.S. FDA approval of Carvykti (ciltacabtagene autoleucel) for relapsed or refractory multiple myeloma. |
| 2022 | Conditional marketing authorization from the European Commission for Carvykti. |
| 2022 | Approval of Carvykti in Japan. |
| 2024 | FDA expanded Carvykti's label to include patients with at least one prior line of therapy. |
Innovations include Legend Biotech's proprietary CAR-T platform, which enabled the development of a BCMA-targeted therapy with dual binding domains, contributing to its deep and durable responses. Long-term data from the CARTITUDE-1 study, presented in Q2 2025, showed that an impressive 33% of patients with multiple myeloma remained progression-free for five years after Carvykti treatment, highlighting its exceptional durability.
BCMA-Targeted CAR-T Therapy
Development of a BCMA-targeted therapy with dual binding domains, leading to deep and durable responses in patients.
Five-Year Progression-Free Survival Data
Presentation of long-term data in Q2 2025 showing 33% of patients remained progression-free five years post-treatment.
Streamlined Monitoring Requirements
FDA's removal of Risk Evaluation and Mitigation Strategies (REMS) for certain CAR-T therapies in 2025, enhancing patient access.
Despite these achievements, Legend Biotech has faced challenges, including the inherent complexities of manufacturing personalized cell therapies and ensuring consistent supply to meet growing demand. Navigating a highly competitive landscape with other CAR-T therapies and bispecific antibodies also presents ongoing hurdles.
Manufacturing Complexities
Addressing the intricate processes involved in producing personalized cell therapies, aiming for 10,000 annualized doses by the end of 2025.
Competitive Landscape
Operating within a crowded market of CAR-T therapies and bispecific antibodies, requiring continuous innovation and strategic positioning.
Regulatory Hurdles
Overcoming temporary setbacks such as clinical holds on pipeline candidates, demonstrating resilience in the regulatory process.
Legend Biotech Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What is the Timeline of Key Events for Legend Biotech?
The Legend Biotech history showcases a remarkable journey from its inception in 2014 to its current position as a significant player in cell therapy. Founded as the 'Legend Project' within GenScript Biotech in Nanjing, China, the company quickly focused on developing BCMA-targeting CAR-T cells, establishing itself as an early pioneer in this innovative field. Key milestones include the commencement of investigator-initiated trials in China in 2016 and a pivotal exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc. for its lead candidate, cilta-cel, in December 2017. The company's public debut on NASDAQ in June 2020 marked a new chapter, followed by significant regulatory approvals for its CAR-T therapy, Carvykti (cilta-cel), in the U.S. in February 2022, Europe in May 2022, and Japan in September 2022. Further expanding its therapeutic reach, the U.S. FDA approved Carvykti for earlier lines of therapy in April 2024. The Legend Biotech company profile highlights its consistent growth and commitment to advancing cancer treatment.
| Year | Key Event |
|---|---|
| 2014 | Legend Biotech founded in Nanjing, China, as the 'Legend Project' within GenScript Biotech, focusing on CAR-T therapies. |
| 2015 | Scientists focus on developing BCMA-targeting CAR-T cells, becoming early pioneers in the field. |
| 2016 | Investigator-initiated trials for cilta-cel begin in China. |
| December 2017 | Exclusive worldwide license and collaboration agreement signed with Janssen Biotech, Inc. for cilta-cel. |
| June 2020 | Legend Biotech completes its Initial Public Offering (IPO) on NASDAQ (LEGN). |
| February 2022 | U.S. FDA approves Carvykti (cilta-cel) for relapsed/refractory multiple myeloma. |
| May 2022 | European Commission grants conditional marketing authorization for Carvykti. |
| September 2022 | Japan's Ministry of Health, Labour and Welfare approves Carvykti. |
| April 2024 | U.S. FDA approves Carvykti for earlier lines of therapy in multiple myeloma. |
| Q1 2025 | Reports collaboration revenue of $185.6 million, and Carvykti net trade sales of approximately $369 million. |
| Q2 2025 | Reports total revenue of $255.1 million and record Carvykti net trade sales of $439 million. Over 7,500 patients treated with Carvykti to date. |
| August 2025 | Announces long-term data from CARTITUDE-1 study showing 33% of patients progression-free at 5 years. |
Financial Milestones and Profitability Goals
Legend Biotech aims for operational breakeven for Carvykti by the end of 2025 and company-wide profitability by 2026. The company reported collaboration revenue of $185.6 million and Carvykti net trade sales of approximately $369 million in Q1 2025, followed by total revenue of $255.1 million and record Carvykti net trade sales of $439 million in Q2 2025.
Manufacturing Expansion and Market Access
Manufacturing capacity is set to expand to 10,000 annualized doses by the end of 2025, with new facility approvals and commercial production at its Tech Lane facility. Strategic initiatives include partnerships with community practices to broaden Carvykti's market access and more than doubling market launches in 2025 compared to 2024.
Pipeline Development and Innovation
The company's pipeline includes promising candidates like LB1908 and LB2102, targeting solid tumors, demonstrating a commitment to diversifying its therapeutic portfolio. This forward-looking strategy is rooted in its founding vision of bringing hope to patients through groundbreaking cell therapies.
Financial Runway and Strategic Investment
With a strong cash position of approximately $1.0 billion as of June 30, 2025, Legend Biotech expects financial runway into the second quarter of 2026. This enables sustained investment in its core differentiators and continued development of cutting-edge cell therapy modalities, reinforcing its Competitors Landscape of Legend Biotech.
Legend Biotech Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Competitive Landscape of Legend Biotech Company?
- What is Growth Strategy and Future Prospects of Legend Biotech Company?
- How Does Legend Biotech Company Work?
- What is Sales and Marketing Strategy of Legend Biotech Company?
- What are Mission Vision & Core Values of Legend Biotech Company?
- Who Owns Legend Biotech Company?
- What is Customer Demographics and Target Market of Legend Biotech Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.